CME Webinar: Delaying Type 1 Diabetes: Early Antibody Screening and Use of Teplizumab in Children
In this webinar, Shideh Majidi, M.D., M.S.C.S., director of the Childhood and Adolescent Diabetes Program at Children’s National Hospital, discussed early antibody screening and use of teplizumab in children.
Key takeaways
- Current state of type 1 diabetes: Type 1 Diabetes (T1D) is characterized by absolute insulin deficiency due to pancreatic beta-cell destruction, often diagnosed in childhood but can occur in adults as well. It requires lifelong insulin management.
- Increased risk and screening: Individuals with family members who have T1D are at higher risk of developing T1D, but most newly diagnosed cases have no family history. Early screening can help reduce diabetic ketoacidosis (DKA) rates and improve management.
- Stages of type 1 diabetes: T1D is classified into three stages: Stage 1 (normal blood sugars with 2 or more autoantibodies), Stage 2 (dysglycemia with 2 or more autoantibodies), and Stage 3 (clinical T1D requiring insulin).
- Early screening and follow-up: Screening for diabetes autoantibodies can be done through various programs and labs. Follow-up involves regular monitoring based on the number of antibodies and blood sugar levels. If patients have antibodies or abnormal blood sugars, they can be referred to the T1Delay Program at Children’s National (through an endocrine/diabetes referral).
- Teplizumab (T-zield) treatment: T-zield is an FDA-approved treatment for delaying the onset of Stage 3 T1D in individuals aged 8 and older with Stage 2 T1D. It involves a 14-day infusion regimen and has been shown to delay insulin need by a median of 2 years.
- Clinical implementation and support: Children’s National offers T-zield treatment through a multi-departmental effort. The program aims to improve both quality of life and clinical outcomes for patients.
More information
- For more information on this webinar, as well as access to the presentation slide deck, visit our website.
- To register for future CME opportunities or view past presentations, visit childrensnational.org/Webinars.
